NDAORALCAPSULEPriority Review
Approved
Apr 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
5/8 — Partial
Priority Review
VIVJOA (oteseconazole) by Mycovia Pharmaceuticals is breast cancer resistance protein inhibitors [moa]. First approved in 2022.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIVJOA (oteseconazole) is an oral azole antifungal that inhibits the Breast Cancer Resistance Protein to enhance antifungal efficacy. It treats invasive fungal infections in patients with limited treatment options. The mechanism targets drug efflux transporters to improve intracellular drug concentrations.
$0.222MPart D
Peak9.5 years to LOEEarly commercial traction with modest Part D claims suggests a niche specialty product requiring focused commercial and medical affairs resources.
Mechanism of Action
Breast Cancer Resistance Protein Inhibitors
Pharmacologic Class:
Azole Antifungal
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections
Started Mar 2019
219 enrolled
Recurrent Vulvovaginal Candidiasis
A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
Started Aug 2018
425 enrolled
Recurrent Vulvovaginal Candidiasis
A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
Started Aug 2018
438 enrolled
Recurrent Vulvovaginal Candidiasis
Career Relevance
Working on VIVJOA offers stability in a specialized antifungal franchise with a long patent runway, but limited job openings suggest a lean, focused team structure. Career growth depends on driving adoption in a niche indication and preparing for eventual LOE post-2031.
Worked on VIVJOA at Mycovia Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.